Literature DB >> 21422401

Accelerated approval of oncology drugs: can we do better?

Susan S Ellenberg.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21422401     DOI： 10.1093/jnci/djr104

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  Seattle Genetics rare cancer drug sails through accelerated approval.

Authors:  Laura DeFrancesco
Journal:  Nat Biotechnol       Date:  2011-10-13       Impact factor: 54.908

2.  When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guilt.

Authors:  Benjamin Djulbegovic; Iztok Hozo
Journal:  BMC Med Res Methodol       Date:  2012-06-22       Impact factor: 4.615

3.  Time-dependent endpoints as predictors of overall survival in multiple myeloma.

Authors:  Jorge Félix; Filipa Aragão; João M Almeida; Frederico J Calado; Diana Ferreira; António B S Parreira; Ricardo Rodrigues; João F R Rijo
Journal:  BMC Cancer       Date:  2013-03-16       Impact factor: 4.430

4.  Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness.

Authors:  Melanie McPhail; Emma Weiss; Tania Bubela
Journal:  Front Med (Lausanne)       Date:  2022-02-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.